|
Affiliation |
Faculty of Medicine College Hospital Blood transfusion department |
|
Title |
Lecturer |
|
External Link |
|
|
Related SDGs |
|
KUBUKI Yoko
|
|
|
Degree 【 display / non-display 】
-
博士(医学） ( 2005.2 宮崎大学 )
-
学士（医学） ( 1986.3 宮崎医科大学 )
Research Areas 【 display / non-display 】
-
Life Science / Hematology and medical oncology
Papers 【 display / non-display 】
-
Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia Reviewed
Muneou Suzuki,Hidenori Sasaki,Takanori Toyama, Kiyoshi Yamashita,Koichi Maeda,Hitoshi Matsuoka,Akihiko Okayama,Hirohito Tsubouchi
Leukemia and Lymphoma 46 ( 3 ) 393 - 399 2005.3
Language：English Publishing type：Research paper (scientific journal)
-
Overeexpression of a cell adhesion molecule,TSLC,as a possible molecular marker for acute-type adult T-cell leukemia Reviewed
Hidenori Sasaki,Ichiro Nishikata,Tomonori Hidaka,Yoko Kubuki,Akihiko Okayama, Hirohito Tsubouchi,Kazuhiro Morishita
BLOOD 105 ( 3 ) 1204 - 1213 2005.2
Language：English Publishing type：Research paper (scientific journal)
-
Possible involvement of neutrophils in a serum level increase of hepatocyte growth factor in non-Hodgkin’s lymphoma Reviewed
外山 孝典,井戸 章雄,佐々木 秀法,前田 宏一,山下 清,久冨木 庸子,鈴木 斎王,松岡 均,坪内 博仁
Oncology Reports 13 ( 3 ) 439 - 444 2005.3
Language：English Publishing type：Research paper (scientific journal)
-
幣 光太郎, 亀田 拓郎, 内田 泰介, 上運天 綾子, 秋月 渓一, 久冨木 庸子, 池田 良磨, 宇都 倫史, 深谷 知宏, 三苫 修也, 佐藤 克明, 上平 雄大, 上野 浩晶, 山口 秀樹, 下田 和哉
Blood Neoplasia 2 ( 3 ) 100087 2025.8
Language：English Publishing type：Research paper (scientific journal) Publisher：Elsevier BV
Interferon-α (IFN-α) exhibits antiviral and antiproliferative effects on normal and neoplastic cells. Intracellular signaling of IFN-α is mediated by tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1), followed by signal transducers and activators of transcription (STATs). TYK2 is redundant for the antiviral effect of IFN-α; however, the requirements for antiproliferative effects are unknown. We assessed the role of TYK2 in the effects of IFN-α in myeloproliferative neoplasm (MPN) model mice. Jak2V617F transgenic mice develop MPNs resembling human primary myelofibrosis, and ropeginterferon-α-2b ameliorated their features. However, these IFN-α effects were absent in Jak2V617F;Tyk2−/− mice. In mixed wild-type (WT)/Jak2V617F chimeric mice, IFN-α treatment induces Jak2V617F hematopoietic stem cells (HSCs) to enter the cell cycle and skew their differentiation into the megakaryocyte lineage, decreasing the number of Jak2V617F HSCs. The effects of IFN-α on Jak2V617F HSCs were not observed in mixed WT/Jak2V617F;Tyk2−/− mice, indicating that TYK2 is essential for the effects of IFN-α on both Jak2V617F progenitors and HSCs. The mechanism of IFN-α in Jak2V617F HSCs and progenitors differed: genes regulating the cell cycle were enriched in IFN-α–stimulated Jak2V617F HSCs, but not in Jak2V617F progenitors; genes regulating antiproliferation were enriched in IFN-α–stimulated Jak2V617F progenitors but not in Jak2V617F HSCs. The major IFN-α signaling molecule activated by JAKs is STAT1, which is essential for the antiviral effect. Most effects of IFN-α on Jak2V617F cells were preserved in Jak2V617F;Stat1−/− mice but to a moderate degree compared with Jak2V617F mice. Our study reveals essential roles of TYK2 for the preferential suppressive effect of IFN-α on Jak2V617F progenitors and HSCs.
-
Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice Reviewed
Kamiunten A., Kameda T., Sekine M., Kawano H., Toyama T., Akizuki K., Kawano N., Maeda K., Sato S., Takeuchi M., Ishizaki J., Nagamine K., Kuroki A., Ikeda R., Matsumoto K., Karasawa M., Tahira Y., Uchida T., Shimoda H., Hidaka T., Yamashita K., Yamaguchi H., Kubuki Y., Shimoda K., Shide K.
International Journal of Hematology 122 ( 1 ) 83 - 92 2025.7
Language：English Publishing type：Research paper (scientific journal) Publisher：International Journal of Hematology
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy with a poor prognosis. We conducted a retrospective study across six institutions in Miyazaki Prefecture, Japan, to assess the efficacy of tucidinostat in patients with relapsed/refractory ATL who had not undergone transplantation. Between October 2021 and July 2023, 24 patients aged 41 to 88 years (median, 73.4 years) who had undergone prior therapies, including intensive chemotherapy (79.2%) and mogamulizumab immunotherapy (79.2%), received tucidinostat. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated as key outcomes. ORR and DCR reached 54.2% and 91.7%, respectively. The median PFS was 3.95 months, and OS was 8.04 months, which were not inferior to the results of a phase IIb study. The influential factors for PFS were age ≥ 75 years and high soluble IL-2 receptor (sIL-2R) levels above 5000 U/mL at the start of treatment. Favorable patients without these factors achieved a PFS of 11.4 months. Treatment-related adverse events were mainly hematologic but were managed over the course of treatment. Our findings indicate that tucidinostat provides survival benefits in patients with relapsed/refractory ATL in clinical practice and highlight key clinical factors for better outcomes.
Books 【 display / non-display 】
-
WHO分類第5版による白血病・リンパ系腫瘍の病態学
久冨木庸子、下田和哉（ Role： Joint author , 骨髄性／リンパ性腫瘍）
中外医学社 2024.12
Language：Japanese Book type：Scholarly book
-
血液専門医テキスト
久冨木庸子,下田和哉（ Role： Joint author , その他の骨髄増殖性疾患）
株式会社 南江堂 2011.10
Language：Japanese Book type：Scholarly book
-
専門医のための薬物療法Ｑ＆Ａ
久冨木庸子、下田和哉（ Role： Joint author , 121-129）
中外医学社 2007.10
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
特集 患者さんからよく尋ねられる内科診療のQuestion 第4章 血液 [40歳女性.特発性血小板減少性紫斑病]歯科で抜歯が必要と言われたのですが,血小板数が8万/μLしかありません.抜歯は可能でしょうか?
久冨木 庸子
内科 133 ( 4 ) 712 - 714 2024.4
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：南江堂
-
歯科で抜歯が必要と言われたのですが,血小板数が8万/μLしかありません.抜歯は可能でしょうか? : 40歳女性.特発性血小板減少性紫斑病
久冨木 庸子
内科 : 臨床雑誌 133 ( 4 ) 712 - 714 2024.4
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：東京 : 南江堂
-
骨髄異形成/骨髄増殖性腫瘍(MDS/MPN)の分類と診断のポイント
久冨木 庸子
血液内科 = Hematology 87 ( 5 ) 519 - 524 2023.11
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：東京 : 科学評論社
-
骨髄標本のスマッジ細胞集簇像が診断の契機となった血管内大細胞型B細胞リンパ腫 Reviewed
河野 克海、橋倉 悠輝、髙木 覚、松浦 成美、長安 真由美、久冨木 庸子、梅北 邦彦
医学検査 71 ( 3 ) 574 - 580 2022.7
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：一般社団法人 日本臨床衛生検査技師会
-
Shimosaki S., Nakahata S., Ichikawa T., Kitanaka A., Kameda T., Hidaka T., Kubuki Y., Kurosawa G., Zhang L., Sudo Y., Shimoda K., Morishita K.
Biochemical and Biophysical Research Communications 530 ( 2 ) 486 2020.9
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Biochemical and Biophysical Research Communications
The authors regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or HH must be corrected from “every 3 days” to “every 3–4 days” in the part of “Supplementary materials and methods”. The authors also regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or Su9T01 must be corrected from “two times per week for 2 weeks” to “on day 1, day 8, day 15, and day 21 post-cell injection” in the part of “Supplementary materials and methods”. These corrections do not change the conclusions of this manuscript. The authors would like to apologise for any inconvenience caused. The correct supplementary materials and methods. In vivo experimental therapy studies. Six-to eight-week-old female NOD/Shi-scid/IL-2Rγnull (NOG) or SCID mice (CLEA Japan) were given a single subcutaneous injection of 2 × 106 MT-2 cells or HH cells suspended in 100 μL PBS-diluted matrigel (BD Biosciences). When the average tumor size reached an approximate volume of 100–150 mm3, the mice were intravenously injected with either PBS, mogamulizumab, or the JST-TFR09 antibody at doses of 10 mg/kg (MT-2) or 20 mg/kg (HH) body weight 4–5 times every 3–4 days. The length and width of each tumor were measured with a caliper twice per week and used to calculate the tumor volume (length × width2/2). For Kaplan-Meier survival analysis of mice, NOG mice were given a single intravenous injection of 1 × 106 MT-2 or Su9T01 cells suspended in 100 μL PBS. At 3 days after inoculation of ATLL cells, the mice were intravenously injected with either PBS or JST-TFR09 on day 1, day 8, day 15, and day 21 post-cell injection. The survival rate of mice was observed for a period of 100 days. The authors would like to apologise for any inconvenience caused.
Presentations 【 display / non-display 】
-
Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia. International conference
Tomoki Ito, MD, PhD ,Teruhito Takakuwa, MD, PhD , Masayuki Hino, MD, PhD , Hirohisa Nakamae, MD, PhD , Kazunori Murai, MD, PhD , Yoko Kubuki, MD, PhD , Kazuya Shimoda, M.D., Ph.D. , Yuji Kumagai, MD, PhD , Yukiya Yamamoto, MD, PhD and Tadashi Matsuura, PhD:
The American society of Hematology 66th Annual Meeting and Exposition ( San Diego, California, USA) The American society of Hematology
Event date： 2024.12.7 - 2024.12.10
Language：English Presentation type：Oral presentation (general)
Venue： San Diego, California, USA
-
1805 Impact of Cooperating Myeloid Gene Mutations on Disease Progression and Survival in Japanese MPN Patients: A Multicenter Study. International conference
Saki Ogawa, Kotaro Shide, M.D.1, Masami Takeuchi, M.D.2*, Kosei Matsue, M.D., Ph.D.2, Takuro Kameda, M.D.1, Masato Yasumi, M.D., Ph.D.3*, Takahiro Karasuno, M.D., Ph.D.3*, Taizo Shimomura, M.D., Ph.D.4*, Hitoshi Suzushima, M.D.4*, Kiyoshi Yamashita, M.D.5*, Noriaki Kawano, M.D., Ph.D.5*, Osamu Imataki, M.D.6*, Norimitsu Kadowaki, M.D., Ph.D.6, Akihito Yonezawa, MD, PhD7*, Eiichi Otsuka, M.D.8*, Yoshio Saburi, M.D.8*, Yuki Tahira, M.D.1*, Ayako Kamiunten, M.D.1*, Keiichi Akizuki, M.D.1*, Masayoshi Karasawa, M.D.1*, Ryoma Ikeda, M.D.1*, Kengo Matsumoto, M.D.1*, Ayuka Kuroki, M.D.1*, Koshiro Nagamine, M.D.1*, Yoko Kubuki, M.D.1* and Kazuya Shimoda, MD, PhD1:
The American society of Hematology 66th Annual Meeting and Exposition ( San Diego, California, USA) The American society of Hematology
Event date： 2024.12.7 - 2024.12.10
Language：English Presentation type：Poster presentation
Venue： San Diego, California, USA
-
The role of STAT1 in the resolution of MPN features by IFN-α in Jak2V617F mice
Yuki Tahira，Kotaro Shide，Takuro Kameda，Ayako Kamiunten，Koshiro Nagamine，Ayuka Kuroki，Ryoma Ikeda，Kengo Matsumoto，Keiichi Akizuki，Yoko Kubuki，Kazuya Shimoda
第86回日本血液学会学術集会 (京都市) 京都大学大学院医学研究科 血液内科学
Event date： 2024.10.11 - 2024.10.13
Language：Japanese Presentation type：Oral presentation (general)
Venue：京都市
-
Retrospective analysis of hematopoietic stem cell transplantation for ATL in University of Miyazaki
Ayako Kamiunten，Koshiro Nagamine，Ayuka Kuroki，Ryoma Ikeda，Kengo Matsumoto，Masayoshi Karasawa，Yuki Tahira，Keiichi Akizuki，Takuro Kameda，Kotaro Shide，Yoko Kubuki，Kazuya Shimoda
第86回日本血液学会学術集会 (京都市) 京都大学大学院医学研究科 血液内科学
Event date： 2024.10.11 - 2024.10.13
Language：Japanese Presentation type：Poster presentation
Venue：京都市
-
Portal vein thrombosis and splenomegaly associated with myeloproliferative neoplasms (骨髄増殖性疾患に合併した門脈血栓症と脾腫)
Koshiro Nagamine，Keiichi Akizuki，Kotaro Shide，Ayuka Kuroki，Ryoma Ikeda，Kengo Matsumoto，Masayoshi Karasawa，Ayako Kamiunten，Yuki Tahira，Takuro Kameda，Yoko Kubuki，Kazuya Shimoda
第86回日本血液学会学術集会 (京都市) 京都大学大学院医学研究科 血液内科学
Event date： 2024.10.11 - 2024.10.13
Language：Japanese Presentation type：Oral presentation (general)
Venue：京都市
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
成人Ｔ細胞性白血病・リンパ腫における遺伝子変異の解析とその意義の解明
Grant number：15K09479 2015.04 - 2018.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
成人Ｔ細胞性白血病・リンパ腫における遺伝子変異の解析とその意義の解明
-
テネシンーＣ由来新規ペプチドを用いた造血幹細胞由来の輸血製剤の開発
Grant number：22591066 2010.04 - 2013.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
テネシンーＣ由来新規ペプチドを用いた造血幹細胞由来の輸血製剤の開発
Other research activities 【 display / non-display 】
-
厚生労働科学研究費補助金（がん臨床研究事業）：成人T細胞白血病（ATL)に対する同種幹細胞移植療法の開発とそのHTLV-1排除機構の解明に関する研究 平成21年度第1回岡村班班会議
2009.07
ATL治療等に関する知見を深めた。